NASDAQ · Biotechnology · USD

GeoVax Labs, Inc. (GOVX) Stock Analysis

GeoVax Labs, Inc. (GOVX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GOVX

$0.48

−$0.02 (−4.73%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GOVX with… →

GOVX Key Statistics

As of Sep 4, 2026

Trading

Open: $0.53
Previous Close: $0.51
Day's Range: 0.48–0.53
52-Week Range: 0.48–18.20
Volume: 549.10K
Beta: 3.65

Valuation

Market Cap: $2.52M
P/E Ratio: unprofitable
EPS (ttm): −5.62

Financials (FY)

Revenue (FY): $2.49M−37.06%
Net Income (FY): −$21.46M
Profit margin: 0.00%
Shares Outstanding: 5.21M
1-Year Return: −97.39%

Dividend and dates

Avg Volume: 684.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GOVX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+14.97%+7.10%−82.60%−42.70%−54.39%−93.08%−88.70%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−88.70%
2025	−93.08%
2024	−54.39%
2023	−42.70%
2022	−82.60%
2021	+7.10%
2020 (partial year)	+14.97%

As of September 4, 2026.

GOVX Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$2.49M	−$21.46M	−862.3%
2024	$3.95M	−$24.99M	−632.0%
2023	$0.00	−$25.97M	—
2022	$81.53K	−$14.02M	−17198.3%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$2.49M	—	−$21.64M	−$21.46M	−862.3%
2024	$3.95M	—	−$25.14M	−$24.99M	−632.0%
2023	$0.00	—	−$26.74M	−$25.97M	—
2022	$81.53K	—	−$14.03M	−$14.02M	−17198.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GOVX Valuation vs Biotechnology Median

Median of 656 stocks

Metric	GOVX	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

GeoVax Labs, Inc. (GOVX) is capitalised at $2.52M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 19 employees.

GOVX last closed at $0.48 on September 4, 2026. That is −$0.02 (−4.73%) against the previous close. Over the past 52 weeks the price has ranged from $0.48 to $18.20. The latest close sits 0.6% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.49M. Against the prior fiscal year total of $3.95M, that is a change of −37.06%. The same year closed with a net loss of $21.46M. The reported profit margin is 0%. Trailing earnings per share are −5.62.

Across the 4 fiscal years on file, revenue moves from $81.53K in 2022 to $2.49M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 3.65. Annualized volatility over the trailing 5 years is 166.6%. The trailing one-year price return is −97.39%. Across 5 years the annualized return works out at −81.30%.

Growth & Income

No dividend is on file for GOVX.

The strongest complete calendar year on file is 2021 at +7.10%; the weakest is 2025 at −93.08%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −88.70% year to date.

Peer Comparison

GeoVax Labs, Inc. (GOVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
GeoVax Labs, Inc.	GOVX	$2.52M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. GeoVax Labs, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Visit website →